Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Thyroid Cancer Drugs Market Size Forecast: How Large Could The Market Become By 2030?
The thyroid cancer drugs market has experienced significant expansion in recent years. From $1.32 billion in 2025, it is projected to reach $1.47 billion in 2026, representing a compound annual growth rate of 11.8%. This historic growth has been driven by factors such as a higher prevalence of thyroid cancer, the uptake of kinase inhibitors, advancements in cancer diagnostics, the growth of oncology-focused healthcare facilities, and broader availability of targeted therapies.
The market for thyroid cancer drugs is projected to experience significant expansion over the coming years. By 2030, its value is anticipated to reach $2.39 billion, driven by a compound annual growth rate (CAGR) of 12.8%. This forecasted growth is fueled by several factors, including the rise of personalized oncology treatments, a growing number of advanced thyroid cancer cases, an increase in clinical trial initiatives, broader adoption of immunotherapy combinations, and higher overall spending on oncology care. Key developments during this period include a greater reliance on targeted multikinase inhibitors, the expanded application of combined drug therapies, a stronger emphasis on managing advanced and treatment-resistant forms of thyroid cancer, a broader use of precision oncology strategies, and improved thyroid cancer management within hospital settings.
Download A Free Sample Report For Comprehensive Market Insights:
Thyroid Cancer Drugs Market Growth Drivers And Industry Catalysts
The projected rise in thyroid cancer cases is anticipated to fuel the expansion of the thyroid cancer drugs market in the coming years. Thyroid cancer involves malignant growths in the thyroid gland, necessitating prompt diagnosis and effective medical interventions to curb disease advancement and spread. This uptick in occurrences is attributed to both enhanced identification via more sensitive diagnostic methods and an increase linked to greater exposure to environmental factors. As the prevalence of thyroid cancer climbs, it drives demand for targeted therapies, immunotherapies, radiopharmaceuticals, and hormone-suppressing drugs, which improve treatment efficacy and long-term survival rates. For example, in September 2025, Cancer Research United Kingdom—a UK-based non-profit dedicated to cancer research and patient care—projected approximately 6,600 new thyroid cancer cases annually by 2038–2040, with incidence rates rising 27% from about 7.3 per 100,000 people per year in 2024–2026 to roughly 9.2 per 100,000. Consequently, the growing frequency of thyroid cancer is accelerating the growth of the thyroid cancer drugs market.
Thyroid Cancer Drugs Market Segments: Where Are The Largest Growth Opportunities?
The thyroid cancer drugs market covered in this report is segmented –
1) By Drug Type: Ipilimumab, Cabozantinib-S-Malate, Caprelsa (Vandetanib), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Nivolumab, Vandetanib, Other Drug Types
2) By Type: Radioiodine Ablation, Thyroid Stimulating Hormone (THS) Suppression, Chemotherapy, Targeted Multikinase Therapy, Other Types
3) By End Users: Hospitals, Oncology Clinics, Research Organizations, Other End-Users
Subsegments:
1) By Ipilimumab: Monotherapy Ipilimumab, Combination Therapy With Ipilimumab
2) By Cabozantinib-S-Malate: Single-Agent Cabozantinib, Combination Therapy With Cabozantinib
3) By Caprelsa (Vandetanib): Vandetanib For Medullary Thyroid Cancer (MTC), Combination Therapy With Vandetanib
4) By Doxorubicin Hydrochloride: Doxorubicin For Chemotherapy, Liposomal Doxorubicin
5) By Lenvatinib Mesylate: Lenvatinib For Differentiated Thyroid Cancer (DTC), Combination Therapy With Lenvatinib
6) By Nivolumab: Monotherapy Nivolumab, Combination Therapy With Nivolumab
7) By Vandetanib: Single-Agent Vandetanib, Combination Therapy With Vandetanib
8) By Other Drug Types: Sorafenib, Everolimus, Pembrolizumab
Thyroid Cancer Drugs Market Trends Influencing Long-Term Demand
Key players in the thyroid cancer market are focused on developing innovative treatments like selpercatinib to enhance patient care and therapeutic outcomes. Selpercatinib, sold under the brand name Retevmo, is used to address various cancers driven by Rearranged During Transfection (RET) mutations, such as advanced or metastatic medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer. As an example, in September 2024, Eli Lilly and Company, a pharmaceutical firm based in the United States, secured approval from the Food and Drug Administration (FDA), a U.S. federal entity tasked with safeguarding public health, for selpercatinib (Retevmo) to treat advanced or metastatic MTC with a RET mutation. This authorization covers both adult and pediatric patients aged two years and older needing systemic therapy. This recent traditional approval represents a major step forward in therapeutic choices for individuals affected by this particular form of thyroid cancer.
Thyroid Cancer Drugs Market Major Participants And Competitive Dynamics
Major companies operating in the thyroid cancer drugs market are AbbVie Inc., AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Company, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Eli Lilly and Company, Exelixis Inc., F. Hoffmann-La Roche Ltd, Ipsen Biopharmaceuticals Inc., Johnson & Johnson, Kyowa Kirin Co. Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Amgen Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH
Access The Complete Thyroid Cancer Drugs Market Report:
Thyroid Cancer Drugs Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the thyroid cancer drugs market in 2025. Middle East is expected to be the fastest-growing region in the thyroid cancer drugs market during the forecast period. The regions covered in the thyroid cancer drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model